RT @iofbonehealth: #Osteoporosis Int: Long-term persistence in patients with osteoporosis receiving #denosumab in routine practice: 36-mont…
#Osteoporosis Int: Long-term persistence in patients with osteoporosis receiving #denosumab in routine practice: 36-month non-interventional, observational study https://t.co/KAn7ePq904 #treatment https://t.co/lecYKRpGAK
RT @Osteoporosis_NL: Long-term persistence in 1158 patients with osteoporosis receiving denosumab in routine practice: 50.7% over 36-month…
RT @Osteoporosis_NL: Long-term persistence in 1158 patients with osteoporosis receiving denosumab in routine practice: 50.7% over 36-month…
RT @Osteoporosis_NL: Long-term persistence in 1158 patients with osteoporosis receiving denosumab in routine practice: 50.7% over 36-month…
Real-world practice data: approx 50% persistence with Dmab at 36 mo #osteoporosis https://t.co/cFIpg75NFH
Long-term persistence in 1158 patients with osteoporosis receiving denosumab in routine practice: 50.7% over 36-months. Borek D et al. Osteoporos Int 22 April 2019 https://t.co/ZlB6KjQW0x